2026-11-06 Earnings
Earnings report D1 +5.3% · since -1.3%
2026-11-06 8-K filing
8-K: Item 2.02, Item 9.01 D1 +5.3% · since -1.3%
2026-11-05 Product Bull
Moderna Advances Bundibugyo Ebolavirus Vaccine to Phase 2/3 WHO confirms adding Moderna's MRNA-1469 as new Ebola trial candidate
D1 -6.5% · since +3.9%
2026-10-29 Capital Bull
Large bullish call options bet on Moderna, expiring Nov 6 Large $250 call buys on Oct 28 with rising open interest, market eyes Nov 6 catalyst
D1 +4.0% · +5d +8.4%
2026-10-27 → 10-28 Analyst
Moderna Rises 4% Despite William Blair Downgrade Investors weigh strong cancer vaccine data against high valuation, stock climbs despite downgrade
D1 +4.6% · +5d +9.8%
› 2 waves of this story2026-10-27 After 545% run, analyst cites valuation concerns in downgrade2026-10-28 Investors weigh strong cancer vaccine data against high valuation, stock climbs despite downgrade2026-10-27 Analyst
William Blair downgrades to Market Perform D1 +4.6% · +5d +9.8%
2026-10-02 → 10-18 Capital Bull
Moderna Joins Nasdaq-100, Shares Around $225, Weekend Buzz M1 confirms Nasdaq-100 inclusion; M2 shows top YTD performer, extending prior event line
D1 +0.6% · +5d +18.4%
› 4 waves of this story2026-10-02 Inclusion in Nasdaq-100 triggers passive buying from index funds, boosting liquidity and institutional attention2026-10-10 Inclusion drives rally, confirmed by multiple sources; sustainability to watch2026-10-11 Friday's double-digit gain tied to index inclusion; retail chatter persists2026-10-18 M1 confirms Nasdaq-100 inclusion; M2 shows top YTD performer, extending prior event line2026-10-13 → 10-17 Other Bear
Moderna Slips 10% as Profit Taking Halts Cancer Vaccine Rally Shares retreat from $242 high to $214; focus shifts to ESMO cancer vaccine data next week
D1 +1.2% · +5d +11.9%
› 3 waves of this story2026-10-13 Multiple sources confirm YTD gain and intraday high, no new fundamental catalyst2026-10-16 Rotation out of AI/tech into healthcare lifts Moderna to new 52-week high2026-10-17 Shares retreat from $242 high to $214; focus shifts to ESMO cancer vaccine data next week2026-10-13 Capital Bull
Moderna Gains $4.2B in Week, Shares Up 5%+ Weekly gain notable despite daily drop; bull-bear divergence widens
D1 +1.2% · +5d +11.9%
2026-10-13 Earnings
Moderna to Report Q3 2026 Results on Nov 6 Company confirms date; market awaits guidance and pipeline updates
D1 +1.2% · +5d +11.9%
2026-10-07 Company
Tempus Expands Collaboration with Moderna and Merck to Support INT Commercialization Tempus to handle sequencing and sample logistics for mRNA-4157 with Keytruda potential commercialization
D1 +4.8% · +5d +15.2%
2026-09-14 → 10-02 Product Bear
Moderna Up 37% in Sept; Citi Warns of 60% Plunge Citi downgrades to Sell citing overextended rally, yet buyers step in, widening bull-bear divide
D1 +1.9% · +5d +17.9%
› 10 waves of this story2026-09-14 AI-driven personalized cancer vaccine met Phase 3 endpoint in adjuvant melanoma with Merck; company cites broader multi-tumor push2026-09-16 Zacks reports positive Phase III results showing significant improvements in recurrence-free and distant metastasis-free survival2026-09-22 First mRNA cancer vaccine to pass Phase 3; data to be presented Oct 24; stock hits 52-week high2026-09-22 Multiple sources confirm ESMO late-breaking abstract, market eyes October data release2026-09-23 CEO and management at Bernstein forum highlight mRNA platform and personalized cancer vaccine intismeran, setting up October Phase 3 data.2026-09-25 Shares near $198; Bernstein reiterates Market Perform with $45 PT2026-09-26 Multiple independent sources confirm new 52-week high and strong performance, extending prior uptrend2026-09-28 NewEdge lifts stake 208%; stock nears top YTD performer, traders keep discussing2026-09-29 Stock continues to climb with high market attention, but no new facts, just repetition.2026-10-02 Citi downgrades to Sell citing overextended rally, yet buyers step in, widening bull-bear divide2026-09-30 Analyst
Citigroup downgrades to Sell D1 -5.4% · +5d +2.0%
2026-09-30 8-K filing
8-K: Item 5.02, Item 7.01, Item 9.01 D1 -5.4% · +5d +2.0%
2026-09-12 → 09-24 Capital
Moderna Sees Institutional Position Changes and Bullish Options Flow Institutional selling and new buying coexist, with bullish options activity indicating heightened interest and divergent views
D1 +1.9% · +5d +17.9%
› 2 waves of this story2026-09-12 Amundi trimmed 1.8% while X posts highlight short squeeze and money flow, showing mixed sentiment2026-09-24 Institutional selling and new buying coexist, with bullish options activity indicating heightened interest and divergent views2026-09-06 → 09-17 Product Bull
Moderna Cancer Vaccine Momentum Extends, Stock Up 137% in Month Multiple sources confirm stock extends monthly rally, no fresh disclosure, continuation of prior event
D1 -3.6% · +5d +2.5%
› 5 waves of this story2026-09-06 Multiple reports highlight breakthrough mRNA cancer vaccine results, boosting oncology pipeline expectations2026-09-07 Moderna bets mRNA's second act on cancer; +394% YTD, 2nd best in S&P 5002026-09-08 Multiple sources highlight progress on melanoma vaccine, drawing high market attention2026-09-15 Price holds high while selling volume dries up; traders see it ready to move again, extending prior rally2026-09-17 Multiple sources confirm stock extends monthly rally, no fresh disclosure, continuation of prior event2026-09-11 Other
Lawmaker Trades MRNA on Day of Vaccine News Two sources flag same-day trades, raising insider trading concerns
D1 +5.4% · +5d +7.0%
2026-09-02 → 09-04 Product Bear
GSK Advances mRNA Flu Vaccine Phase III, Intensifying Competition with Moderna GSK's mRNA flu vaccine advancement directly challenges Moderna's FDA-approved mFlusiva
D1 -2.2% · +5d -9.4%
› 2 waves of this story2026-09-02 GSK to start Phase III mRNA flu vaccine in Sept, signaling heightened competition in mRNA space2026-09-04 GSK's mRNA flu vaccine advancement directly challenges Moderna's FDA-approved mFlusiva2026-09-03 Analyst
Rothschild & Co downgrades to Sell D1 -1.3% · +5d -3.3%
2026-09-03 Analyst Bear
Moderna Downgraded to Sell, PT Raised to $81 Rothschild Redburn sees strong melanoma data but valuation prices in broad use
D1 -1.3% · +5d -3.3%
2026-09-02 8-K filing
8-K: Item 1.01, Item 2.03, Item 3.02, Item 8.01 D1 -2.2% · +5d -9.4%
2026-08-28 Analyst
Argus Research upgrades to Buy D1 -3.3% · +5d +5.5%
2026-08-28 Regulation
FDA clears updated COVID shots incl. Moderna's 2026-27 season approvals for Moderna, Pfizer, Novavax-Sanofi
D1 -3.3% · +5d +5.5%
2026-08-25 Analyst
Wolfe Research upgrades to Peer Perform D1 +14.4% · +5d -2.9%
2026-08-19 Analyst
William Blair upgrades to Outperform D1 +177.0% · +5d -14.2%
2026-08-06 → 08-07 Regulation Bull
FDA Approves Moderna's First mRNA Flu Vaccine mFLUSIVA FDA approves Moderna's first mRNA flu vaccine for adults 50+, with supply expected in select retailers in coming weeks.
D1 -4.3% · +5d +18.2%
› 2 waves of this story2026-08-06 Multi-source confirmed; new option for seniors; fifth approved product globally2026-08-07 FDA approves Moderna's first mRNA flu vaccine for adults 50+, with supply expected in select retailers in coming weeks.2026-08-05 Insider selling Bear
Insider selling $28.7M (1) D1 -1.3% · +5d +13.2%
2026-07-31 Earnings
Moderna Q2 Revenue Beats but Loss Widens Q2 revenue of $145M beat estimates, EPS loss of $1.97, but COVID vaccine sales weak
D1 -5.4% · +5d +7.9%
